Barometers erase early losses; Nifty trades above 25,100
At 12:30 ST, the barometer index, the S&P BSE Sensex, rose 125.24 points or 0.15% to 82,327.51. The Nifty 50 index added 16.35 points or 0.06% to 25,106.45.
In the broader market, the S&P BSE Mid-Cap index shed 0.38% and the S&P BSE Small-Cap index rose 0.06%.
The market breadth was negative. On the BSE, 1,840 shares rose and 1,977 shares fell. A total of 219 shares were unchanged.
Economy:
India's core industries comprising eight sectors reported 1.7% growth in June 2025, down from 5% in the same month of 2024, data released on Monday by Ministry of Commerce and Industry showed.
On a month-on-month basis, the expansion in June is relatively up, when these key sectors grew by 1.2%.
Commerce ministry data showed the production of steel, cement and refinery products recorded positive growth in June 2025.
The Index of Eight Core Industries (ICI) measures the combined and individual performance of production of eight core industries -- Coal, Crude Oil, Natural Gas, Refinery Products, Fertilizers, Steel, Cement and Electricity.
The Eight Core Industries comprise 40.27% of the weight of items included in the Index of Industrial Production (IIP).
The cumulative growth rate of ICI during April to June, 2025-26 is 1.3% (provisional) as compared to the corresponding period of last year.
Derivatives:
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, slipped 2.61% to 10.91. The Nifty 31 July 2025 futures were trading at 25,125 at a premium of 18.55 points as compared with the spot at 25,106.45.
The Nifty option chain for the 31 July 2025 expiry showed a maximum call OI of 60.7 lakh contracts at the 25,500 strike price. Maximum put OI of 54.6 lakh contracts was seen at 25,000 strike price.
Buzzing Index:
The Nifty Pharma index slipped 0.98% to 22,311.70. The index fell 1.62% in three consective trading sessions.
Granules India (down 3%), Aurobindo Pharma (down 2.64%), Lupin (down 2.26%), Gland Pharma (down 2.19%), Dr Reddys Laboratories (down 1.69%), Laurus Labs (down 1.22%), Divis Laboratories (down 1.05%), Ajanta Pharma (down 0.99%), Torrent Pharmaceuticals (down 0.93%) and Zydus Lifesciences (down 0.93%) declined.
On the other hand, Natco Pharma (up 1.29%), Mankind Pharma (up 1.15%) and Abbott India (up 0.28%) edged higher.
Stocks in Spotlight:
Titan Company advanced 1.42% after the company announced that it has entered into an agreement for acquiring 67% shareholding in Damas LLC (UAE), the current holding company for Damas jewellery business in GCC countries.
Dev Information Technology (DEV IT) jumped 5.38% after the company announced that it has secured an order worth Rs 1.29 crore from the National Informatics Centre Services Incorporated (NICSI.
Latent View Analytics rallied 3.02% after the company reported 30% jump in consolidated net profit to Rs 50.6 crore on a 31.9% increase in total revenue from operations to Rs 236 crore in Q1 FY26 as compared with Q1 FY25.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
8 minutes ago
- Business Standard
Bank of Baroda stock fluctuates after mixed Q1 show; hold or exit?
Shares of Bank of Baroda recouped losses after it fell over 2 per cent on Monday morning deals as analysts termed the lender's first quarter performance as a mixed bag, with a modest growth in net profit. The public-sector lender's stock fell as much as 2.33 per cent during the day to ₹237.7 per share, the biggest intraday rise since June 19 this year. However, the stock pared losses to trade 0.3 per cent higher at ₹244.3 apiece, compared to a 0.02 per cent decline in Nifty 50 as of 11:00 AM. Shares of the company have been in a range-bound pattern since June. The counter has risen 1.5 per cent this year, compared to a 5 per cent advance in the benchmark Nifty 50. Bank of Baroda has a total market capitalisation of ₹1.26 trillion. Bank of Baroda Q1 results The lender's net profit grew 1.9 per cent year-on-year (Y-o-Y) to ₹4,541 crore in the first quarter of 2025-26 (Q1FY26), aided by treasury income, amid pressure on net interest margin. Net interest income (NII) -- the difference between interest earned and interest expended -- fell 1.4 per cent Y-o-Y to ₹11,435 crore. Net interest margin (NIM) from domestic operations fell to 2.91 per cent in Q1FY26, down from the 3.18 per cent in Q1FY25. BoB reported 12.6 per cent Y-o-Y credit growth in overall advances to ₹12.07 trillion. The domestic book grew by 12.4 per cent. While retail advances increased 17.5 per cent, corporate loans saw 4.2 per cent Y-o-Y growth in Q1FY26. Home loans grew by 16.5 per cent. Bank of Baroda asset quality The asset quality profile improved with gross non-performing assets (NPAs) declining to 2.28 per cent from 2.88 per cent a year ago. The net NPAs fell to 0.60 per cent from 0.69 a year ago. The provision coverage ratio, including those for write-offs, stood at 93.18 per cent in June 2025. Lender's capital adequacy ratio stood at 17.19 per cent with the common equity tier I (CET-1) of 17.61 per cent. Analysts on Bank of Baroda Q1 The lender reported a mixed performance in Q1FY26, marked by slower loan growth, higher slippages, and a relatively resilient NIM, Nuvama Institutional Equities said. While BoB's international loan quality remains more volatile than peers, overseas loan growth continues to outpace domestic, Nuvama said. NIM resilience was aided by slower marginal cost of funds-based lending rate (MCLR) cuts and repricing of bulk deposits, despite having a similar external benchmark lending rate (EBLR) mix of 48 per cent as peers. However, Nuvama anticipates a sharper NIM decline for BoB in the coming quarters. Nuvama raised its target price to ₹280 (from ₹260), and maintained its rating at 'Buy'. The near-term pressure on NIMs is expected to continue before a potential recovery in the second half of the financial year, Axis Securities said. A sharper-than-expected contraction in NIMs could pose risks to the bank's ability to deliver a 1 per cent return on assets (RoA), it said The bank is actively working to strengthen its fee income profile, while operating expense growth is expected to remain controlled and slightly below business growth, Axis said. "With no major asset quality concerns on the horizon, credit costs are likely to stay contained, it added. ALSO READ: Analysts at Antique Stock Broking said that the bank delivered a mixed performance, with RoA supported by higher non-core income and a relatively smaller contraction in NIM compared to peers. However, elevated credit costs and higher slippages were notable concerns, it said. Bank of Baroda has consistently maintained RoA above 1 per cent for the past 12 quarters, and this trend is expected to continue, Antique said. The stock appears reasonably priced, with the brokerage maintaining its 'Buy' rating.
Mint
10 minutes ago
- Mint
Shares to buy for the short term: Jigar Patel of Anand Rathi recommends THESE 2 stocks
Shares to buy for the short term: The Indian stock market has been in corrective mode for the last few weeks due to the delayed India-US trade deal, the foreign capital outlook, and uninspiring Q1 earnings. The Sensex and the Nifty 50 have been on losing streak for the last four consecutive weeks, on a weekly basis. So far this month, both indices are down nearly 3 per cent each. Last Friday, the Nifty 50 fell almost 1 per cent to end at 24,837, falling below its critical support of 25,000. Jigar S. Patel, Senior Manager of Equity Research at Anand Rathi Share and Stock Brokers, underscored that the Nifty's reversal from 25,250 has brought it precariously close to a breakdown below the previous swing low at 24,850, a development considered negative for market sentiment. Patel pointed out that the index is now hovering around a crucial rising channel support, and a close below 24,800 could confirm this breakdown, placing the next support at 24,450 in the spotlight. A breach of the 24,450 may usher in a more pronounced corrective phase. On the upside, recapturing the 25,000 level will be essential for the bulls to regain momentum, said Patel. The expert further added that from a positioning perspective, the current long-short ratio in index futures has dropped below 15 per cent, signalling a predominance of short bets. "While this high concentration of shorts increases nervousness, it also raises the odds for a sharp short-covering rally if a positive trigger emerges. Until clearer signals appear, a cautious outlook on the broader time frame is recommended," said Patel. Jigar Patel recommends buying shares of TCS and Sun Pharma for the next two to three weeks. TCS has been on a downward trajectory since mid-May 2025, consistently forming lower highs and lower lows. This bearish structure has resulted in a correction of nearly ₹ 440 — a decline of approximately 12.32 per cent. However, the stock now stands at a technically significant zone, where both time and price confluence suggest a potential trend reversal. Historically, key pivot highs and lows in TCS have often occurred within a 25–38 day cycle. Interestingly, this window aligns with both the Lucas number (29) and Fibonacci number (34), adding credence to the time-based support. Adding to the technical outlook, a bullish Bat Harmonic Pattern is taking shape around the ₹ 3,080-3,100 mark, coinciding with the S1 quarterly floor pivot, reinforcing the likelihood of a strong base. Moreover, the MACD histogram is showing signs of exhaustion in negative momentum, with shrinking red bars indicating a possible shift in trend. "In light of these technical factors, traders may consider initiating long positions in the ₹ 3,140–3,100 zone in a staggered manner, targeting an upside move toward ₹ 3,430, with a protective stop loss at ₹ 2,965 on a daily closing basis,' said Patel. TCS technical chart Sun Pharma has formed a robust base in the ₹ 1,650–1,680 range, coinciding with the S3 Camarilla monthly pivot, signalling a key support zone. This area also aligns with a rising trendline and the lower median line of a pitchfork, creating a compelling technical confluence that could attract renewed buying interest. "The multiple support factors at play increase the probability of a bullish reversal from current levels. A decisive move above this consolidation zone could open the door for a fresh leg higher,' said Patel. Patel suggests an entry zone of ₹ 1,705–1,695 for the stock, with a target price of ₹ 1,800, and a stop loss of ₹ 1,650 on a daily closing basis. Sun Pharma technical chart Read all market-related news here
Business Standard
10 minutes ago
- Business Standard
Barometers pare losses; Nifty trades above 24,850
The headline equity benchmarks pared all early losses and traded with minor gains in the morning trade. The Nifty traded above the 24,850 mark. Realty shares witnessed selling pressure for the fifth consecutive trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex rose 57.70 points or 0.08% to 81,517.51. The Nifty 50 index added 31.40 points or 0.12% to 24,864.85. In the broader market, the S&P BSE Mid-Cap index rallied 0.60% and the S&P BSE Small-Cap index rose 0.24%. The market breadth was positive. On the BSE 2,028 shares rose and 1,664 shares fell. A total of 209 shares were unchanged. Economy: India's forex reserves dipped by $1.18 billion to $695.49 billion for the week ending July 18, data by the Reserve Bank of India showed on Friday. For the week ended July 18, foreign currency assets, a major component of the reserves, slipped by $1.201 billion to $587.609 billion, the data released on Friday showed. However, the gold reserves increased by $150 million to $84.499 billion during the week, the RBI said. The Special Drawing Rights (SDRs) were down by $119 million to $18.683 billion, the apex bank said. India's reserve position with the IMF declined by $13 million to $4.698 billion in the reporting week, the apex bank data showed. Result today: Adani Green Energy (up 2.12%), Apollo Micro Systems (down 2.15%), Indusind Bank (down 0.45%), Mazagon Dock Shipbuilders (down 0.75%), JK Paper (down 1.62%), KEC International (up 0.83%), Laxmi Organic Industries (up 0.12%), Mold-Tek Packaging (up 0.95%), Motherson Sumi Wiring India (down 1.01%), NTPC Green Energy (up 2.17%), Paradeep Phosphates (up 5.35%), Piramal Pharma (up 1.06%), Quess Corp (down 0.84%), RailTel Corporation of India (down 1.64%), Sanghi Industries (up 0.39%), Transport Corporation of India (down 1.37%), Thangamayil Jewellery (up 0.46%), Torrent Pharmaceuticals (down 0.09%), TTK Prestige (up 0.08%), UPL (up 0.18%) and Vijaya Diagnostic Centre (up 0.92%) will announce their quarterly results later today. Buzzing Index: The Nifty Realty index dropped 2.90% to 923.05. The index slumped 8.26% in five consecutive trading sessions. Lodha Developers (down 4.37%), DLF (down 2.8%), Prestige Estates Projects (down 2.24%), Brigade Enterprises (down 1.77%), Phoenix Mills (down 1.64%), Oberoi Realty (down 1.55%), Raymond (down 1.25%), Godrej Properties (down 1.24%) and Sobha (down 0.88%) declined. Stocks in Spotlight: ACME Solar Holdings surged 9.16% after the companys consolidated net profit stood at Rs 130.83 crore in Q1 FY26, steeply higher than Rs 1.39 crore in Q1 FY25. Revenue from operations jumped 65% YoY to Rs 510.98 crore in Q1 June 2025. Reliance Infrastructure advanced 2.32% after the company reported a consolidated net profit of Rs 59.84 crore in Q1 FY26, compared to a net loss of Rs 233.74 crore posted in Q1 FY25. Revenue from operations fell 17.86% to Rs 5,907.82 crore in the quarter ended 30 June 2025.
